Immunovant IMVT 深 沪
已收盘 11-13 16:00:00 美东时间
34.18
-0.870
-2.48%
华盛通- 最 高34.84
- 今 开34.71
- 成交量 86.49万股
- 最 低 33.87
- 昨 收 35.05
- 总市值 70.73亿
- 52周最高 45.42
- 市盈率 静 --
- 换手率 0.42%
- 52周最低 21.93
- 委 比 87.50%
- 总股本 2.07亿
- 历史最高 53.75
- 量 比 0.39
- 振 幅 2.77%
- 历史最低 3.145
- 每 手 1
- 风险率 6.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行维持英伟达"超配"评级！但目标价从315美元降至300美元
今日重点评级关注：花旗：维持Faeth Therapeutics"买入"评级，目标价从55美元升至60美元；HC Wainwright & Co.：维持Ocular Therapeutix"买入"评级，目标价从25美元升至28美元
11-11 10:50
Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $47
Wells Fargo analyst Derek Archila maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $45 to $47.
11-10 22:59
电话会总结 ｜ Immunovant(IMVT)2027财年Q2业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• # Immunovant业绩回顾摘要（截至2026年9月30日第二财季） ## 1. 财务业绩 **收入情况：** - LISRAYA净收入为3,100万美元，为该药品2026年8月获批后前五周上市期间录得的收入。该收入中包含了截至9月30日由专科药房持有的、尚未配发的相当数量药品库存。 **费用情况：** - 研发费用（R&D）为8,500万美元； - 一般及行政费用（G&A）为1,910万美元。 **亏损情况：** - 净亏损为9,720万美元，合每股亏损0.47美元。 **现金状况：** - 截至2026年9月30日，Immunovant现金头
11-10 12:30
Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study
Immunovant (NASDAQ:IMVT) announced on Monday positive efficacy results from a clinical trial evaluating IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis (D2T RA). The company confirmed that its 600 mg dose met the primary endpoint, clearing the way for regulatory discussions with t...
11-10 01:23
Immunovant Files Prospectus For Offering Mixed Shelf; Terms Undisclosed
https://www.sec.gov/Archives/edgar/data/1764013/000176401326000124/imvt-formsx3asr2026v1.htm
11-09 20:50
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Immunovant, Inc. announced it will report its second fiscal quarter financial results for the period ended September 30, 2026 on November 9, 2026 before market open. Roivant Sciences Ltd., Immunovant's majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that day, including a business update for Immunovant. Registration details and webcast information are available on the Immunovant website. Immunovant is a clinical-...
10-21 11:00
Roivant Sciences added to Citi's 90-day catalyst watch
Citi has added Roivant Sciences (ROIV) to its 90-day positive catalyst watch due to a release of topline data from the phase 3 CLARITY trial for brepocitinib in non-infectious uveitis coming later thi...
10-13 22:56
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 450 points on Thursday. Shares of argenx SE – ADR (NASDAQ:ARGX) fell sharply in pre-market trading after the company announced plans to discontinue Phase 3 UNITY study of efgartigimod subcutaneous in adults with moderate...
10-08 20:07
Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Applied Digital Corp (NASDAQ:APLD) rose sharply in pre-market trading after the company posted better-than-expected financial results for the first quarter. Applied Digital reported first-quarter adjusted revenue of $300.39 million, beating analyst estimates of $132.16 million, according t...
10-08 16:32
Immunovant Ends Autoimmune Skin Disorder Program
Roivant Sciences Ltd. (NASDAQ:ROIV) announced that Immunovant Inc. (NASDAQ:IMVT) plans to halt the development of IMVT-1402 as a treatment for cutaneous lupus erythematosus (CLE). The decision follows recent proof-of-concept trial results that failed to reach statistical significance. Shares of both...
09-23 21:03
